

# Catherine Handy Marshall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3666178/publications.pdf>

Version: 2024-02-01

26  
papers

2,131  
citations

687363

13  
h-index

580821

25  
g-index

27  
all docs

27  
docs citations

27  
times ranked

5996  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	13.7	1,395
2	Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium. <i>Annals of Internal Medicine</i> , 2019, 171, 756.	3.9	227
3	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , 2019, 76, 452-458.	1.9	109
4	Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 59-65.	3.9	67
5	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 14-21.	1.9	51
6	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021, 79, 692-699.	1.9	49
7	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1623-1630.	7.0	33
8	Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100164.	1.7	22
9	Clinical and genomic features of SPOP-mutant prostate cancer. <i>Prostate</i> , 2022, 82, 260-268.	2.3	20
10	Cardiorespiratory fitness and incident lung and colorectal cancer in men and women: Results from the Henry Ford Exercise Testing (FIT) cohort. <i>Cancer</i> , 2019, 125, 2594-2601.	4.1	19
11	Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	3.0	17
12	CDK12 inactivation across solid tumors: an actionable genetic subtype. <i>Oncoscience</i> , 2019, 6, 312-316.	2.2	15
13	Coronary Artery Calcium as a Synergistic Tool for the Age- and Sex-Specific Risk of Cardiovascular and Cancer Mortality: The Coronary Artery Calcium Consortium. <i>Journal of the American Heart Association</i> , 2020, 9, e015306.	3.7	15
14	Coronary Artery Calcium and the Age-Specific Competing Risk of Cardiovascular Versus Cancer Mortality: The Coronary Artery Calcium Consortium. <i>American Journal of Medicine</i> , 2020, 133, e575-e583.	1.5	12
15	Therapeutic targeting of the DNA damage response in prostate cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 216-222.	2.4	11
16	Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021, 128, 366-373.	2.5	11
17	Association between coronary artery calcium and cardiovascular disease as a supporting cause in cancer: The CAC consortium. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100119.	3.0	10
18	Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2021, 87, 3-12.	2.2	10

#	ARTICLE	IF	CITATIONS
19	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	2.3	10
20	Coronary artery calcium is associated with increased risk for lung and colorectal cancer in men and women: the Multi-Ethnic Study of Atherosclerosis (MESA). <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 708-716.	1.2	7
21	Fitness and prostate cancer screening, incidence, and mortality: Results from the Henry Ford Exercise Testing (FIT) Project. <i>Cancer</i> , 2021, 127, 1864-1870.	4.1	6
22	Healthy Lifestyle Benefits Both Cancer and Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2021, 3, 675-677.	4.0	6
23	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. <i>Journal of Urology</i> , 2021, 206, 623-629.	0.4	4
24	Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 183-188.	1.9	3
25	Mounting Weight of Evidence on the Importance of Body Weight for Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2007-2009.	1.6	2
26	Making National Cancer Instituteâ€œDesignated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. <i>JMIR Cancer</i> , 2022, 8, e33859.	2.4	0